论文部分内容阅读
经皮穿刺无水酒精注射塞(PercutaneousEthanol Injection Therapy,PEIT)最早在1983年由 Sugura 等创用。在大多数病例 PEIT 可使肿瘤彻底坏死。适应证:主要用肝细胞癌(HCC)。适用于瘤体<5cm,特别是<3的 HCC。瘤灶超过3个时,宜与化栓治疗合用。PEIT 对肝功能仅有轻微而短暂的损伤,故对肝功已属 Child C 级的患者也可使用。由于转移性肝癌肝纤维比较多,质地硬,酒精不易弥散和存留,故效果较差。禁忌证:无法控制的腹水,显著的出血倾向
Percutaneous Ethanol Injection Therapy (PEIT) was first created in 1983 by Sugura et al. PEIT can completely necrosis the tumor in most cases. Indications: Hepatocellular carcinoma (HCC) is mainly used. Suitable for tumors <5cm, especially <3 HCC. When there are more than 3 tumors, they should be combined with thrombolytic therapy. PEIT has only mild and transient damage to liver function, so it can be used for patients whose liver function is already Child C. Because metastatic liver cancer has more liver fibers and hard texture, alcohol is not easily dispersed and persists, so the effect is poor. Contraindications: uncontrolled ascites, significant bleeding tendency